Neoadjuvant immunotherapy improves outlook in high-risk melanoma
Malaria booster vaccine continues to meet WHO-specified 75% efficacy goal
11 September 2022HER2-low metastatic breast cancer patients report preserved quality of life with trastuzumab deruxtecan treatment
12 September 2022Neoadjuvant immunotherapy improves outlook in high-risk melanoma
Patients with high-risk melanoma who received the immunotherapy drug pembrolizumab both before and after surgery to remove cancerous tissue had a significantly lower risk of their cancer recurring than similar patients who received the drug only after surgery.
